



Innovative Drug Uses Decoy Principle To Fight Enveloped Viruses

The COVID-19 pandemic has already infected > 120,000 and killed > 4,700 individuals

(Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE - accessed 13 March 2020)



COVID-19 is an enveloped virus belonging to the Coronavirus family, which is already notorious for the SARS and MERS outbreaks. COVID-19 is characterized by a fast pace of transmission and has already generated 10 times as many cases as SARS in a quarter of the time.




Our Solution

Based on recent studies, CX-Viro prevents viral attack on host cells and thereby halts viral multiplication and spread

CX-Viro, produced by Combioxin SA, a Swiss start-up company, acts as a decoy to which the viral envelope preferentially binds instead of entering host cells. CX-Viro thus sucks away the virus, preventing it from attacking host cells and from multiplying.

CX-Viro targets the fundamental first step of COVID-19 infection: viral entry into host cells



About CX-Viro

CX-Viro is a two-pronged anti-infective drug that was recently tested in humans as CAL02 and proved to be safe and well tolerated (*Laterre et al. The Lancet ID 2019*). Based on initial results against enveloped viruses, further studies are needed to confirm its potential for viral destruction in individuals suffering from Coronavirus infections.

To set up a meeting, contact: Samareh Lajaunias, PhD (General Partner) – samareh.lajaunias@combioxin.com



Combioxin SA, Geneva, Switzerland
www.combioxin.com